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Abstract
Background Hyposmia can develop with age and in neurodegenerative conditions, including Parkinson’s disease (PD). The 
University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item smell test widely used for assessing hyposmia. 
However, in a number of situations, such as identifying hyposmic individuals in large populations, shorter tests are preferable.
Methods We assessed the ability of shorter UPSIT subsets to detect hyposmia in 891 healthy participants from the PRE-
DICT-PD study. Shorter subsets included Versions A and B of the 4-item Pocket Smell Test (PST) and 12-item Brief Smell 
Identification Test (BSIT). Using a data-driven approach, we evaluated screening performances of 23,231,378 combinations 
of 1–7 smell items from the full UPSIT to derive “winning” subsets, and validated findings separately in another 191 healthy 
individuals. We then compared discriminatory UPSIT smells between PREDICT-PD participants and 40 PD patients, and 
assessed the performance of “winning” subsets containing discriminatory smells in PD patients.
Results PST Versions A and B achieved sensitivity/specificity of 76.8%/64.9% and 86.6%/45.9%, respectively, while BSIT 
Versions A and B achieved 83.1%/79.5% and 96.5%/51.8%. From the data-driven analysis, 2 “winning” 7-item subsets sur-
passed the screening performance of 12-item BSITs (validation sensitivity/specificity of 88.2%/85.4% and 100%/53.5%), 
while a “winning” 4-item subset had higher sensitivity than PST-A, -B, and even BSIT-A (validation sensitivity 91.2%). 
Interestingly, several discriminatory smells featured within “winning” subsets, and demonstrated high-screening perfor-
mances for identifying hyposmic PD patients.
Conclusion Using abbreviated smell tests could provide a cost-effective means of large-scale hyposmia screening, allowing 
more targeted UPSIT administration in general and PD-related settings.
Keywords Hyposmia · Parkinson’s disease · UPSIT · Smell tests · PREDICT-PD
Introduction
A reduced ability to detect and recognise smells (hypos-
mia) commonly develops with increasing age [1], and can 
occur in otherwise healthy individuals as a result of head 
trauma, viral diseases including upper respiratory tract infec-
tions, sinusitis, or from inhalation of toxic fumes [1, 2]. In 
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addition, hyposmia is increasingly recognised as an early 
feature of several age-related neurodegenerative disorders, 
including Parkinson’s disease (PD) [2, 3]. Indeed, hyposmia 
is observed in up to 90% of PD patients [4], and is con-
sidered a sensitive non-motor symptom for discriminating 
between PD patients and healthy controls [5]. The onset 
of hyposmia is associated with an increased risk of being 
diagnosed with PD [6–8], and can predate motor symptoms 
by years [9, 10]. The neural substrate behind olfactory dys-
function in PD is incompletely understood; however, neu-
ropathological evidence points to the olfactory bulb being 
among the first regions to demonstrate neuronal loss and 
accumulation of intracytoplasmic a-synuclein rich Lewy 
bodies [11–13], before the pathology involves more central 
regions. Thus, olfactory dysfunction is increasingly recog-
nised as a potential marker for the early identification of 
neurodegenerative processes [14–16].
Several smell tests have been created to screen for 
olfactory dysfunction, including tests of odour adapta-
tion, discrimination, detection, identification, memory, and 
suprathreshold intensity scaling [17]. The University of 
Pennsylvania Smell Identification Test (UPSIT), marketed 
by Sensonics International as the Smell Identification Test, is 
one of the most commonly-used smell tests worldwide [18], 
and comprises 40 “scratch-and-sniff” microencapsulated 
odorant strips divided across 4 booklets (10 in each). For 
each strip, participants are required to identify the correct 
smell from a forced choice of 4 possible answers. The total 
number of smells correctly identified out of 40 is then com-
pared with normative age- and sex-specific thresholds for 
olfactory dysfunction [18]. Its popularity reflects its ability 
to be self-administered, to differentiate among different lev-
els of less-than-total dysfunction, and to detect malingering.
Shorter smell identification tests have also been devel-
oped, either as standalone [versions of 12-item Brief Smell 
Identification Test (BSIT)] or preliminary tests [versions of 
4-item Pocket Smell Test (PST)], to guide later adminis-
tration of the UPSIT to relevant individuals (see Supple-
mentary Table 1). A comprehensive list of these and other 
smell tests developed have been reviewed elsewhere [19]. 
Overall, these tests provide utility in the general assessment 
of olfactory dysfunction, and some have shown sensitivity 
for certain neurodegenerative diseases [20, 21]. However, to 
date, there are no smell tests which can confirm the aetiology 
of particular cause of olfactory dysfunction.
In this study, we examined the screening performance of 
the current 4-item PSTs and 12-item BSITs in a large group 
of healthy, older individuals from the PREDICT-PD study, 
and assessed the tests’ ability to detect hyposmia accord-
ing to the full 40-item UPSIT. We then sought to identify 
novel subset(s) of UPSIT items with superior predictive 
capabilities in the same group, and validated the findings in 
an independent group of individuals from the same study. 
We hypothesised that smells from these “winning” subsets 
could be used as a more accurate and cost-effective pre-
screening tool for olfactory dysfunction, and thus assessed 
certain “winning” subsets on their performance in detecting 
hyposmia in individuals with PD.
Methods
Participant details
We used data from the PREDICT-PD cohort, a study of 1323 
individuals recruited from the general population in the UK 
between the ages of 60–80. Details of recruitment into the 
PREDICT-PD study have been described elsewhere [22]. Of 
the 1067 participants from the PREDICT-PD cohort who 
were sent the full 40-item US version of the UPSIT in the 
baseline year of the study, 891 completed the test that year 
(mean age 67.3 years, SD 4.8, 61.5% female). A group of 
191 participants who completed the UPSIT test in only year 
3 of the study were used for the validation of “winning” 
smell subsets (mean age 69.8 years, SD 4.7, 61.8% female). 
Figure 1 outlines the workflow of UPSIT data collection 
from the PREDICT-PD study.
A separate group of 40 individuals with established PD, 
who were positive controls for the PREDICT-PD study 
(mean age 63.8, SD 9.6, 25% female) were also sent and 
returned the full 40-item UPSIT.
Assessment of current abbreviated smell tests
Shorter smell tests marketed by Sensonics International 
include Versions A and B of the 4-item PST. A test subject 
is recommended to undergo full UPSIT testing if they can-
not correctly identify 1 or more smells in either PST ver-
sion. The original selection of smells in each version of the 
PST was based upon their relevance to diet and nutrition, 
household, and public safety, rather than empirical evidence 
relating to smell identification [23]. Of the abbreviated stan-
dalone tests for olfactory dysfunction by the same company, 
the BSIT is a validated, cross-cultural 12-item version of the 
UPSIT [24]. Notably, the smells and response alternatives 
in BSIT Versions A and B have shown to possess some dis-
criminatory power for specific neurodegenerative diseases 
according to the studies on which they were based; BSIT-A 
for AD [20], and BSIT-B for PD [21], although they do not 
confirm a diagnosis of either disease [19].
Scores for all 40 UPSIT smells were recorded for each 
participant. ‘Hyposmia’ was defined as being the lowest 15th 
centile of UPSIT scores according to age and sex (in 5-year 
bins). This method was used over pre-set threshold scores 
defined within the UPSIT administration manual, given 
that these thresholds were derived from a US population 
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and the current study was undertaken in UK participants. 
Participants with smell scores below the hyposmic thresh-
olds included those who were anosmic (i.e., had complete 
smell loss). Screening performance of each abbreviated 
smell test for hyposmia detection was assessed against the 
corresponding total UPSIT scores for each participant. For 
the 4-item PST and 12-item BSIT versions, scores of ≤ 3 
and ≤ 9, respectively, were indicative of a positive hypos-
mia screen. Sensitivity, specificity, positive predictive value 
(PPV). and negative predictive value (NPV) were calculated 
for each test.
Data‑driven approach to identify novel optimal 
smell subsets
The discovery phase for novel smell subsets was under-
taken using data from the 891 healthy participants (discov-
ery cohort) and assessed all 23,231,378 possible combina-
tions of 1–7 smells from the total of 40 UPSIT smells. For 
each smell combination, the ability to detect hyposmia was 
assessed against the full UPSIT score, and was defined in 
terms of sensitivity, specificity, PPV and NPV, as well as dif-
ferent score thresholds for defining hyposmia. For example, 
for each of the 18,643,560 combinations of 7 smell subsets 
from the full set of 40, we assessed screening performance 
based upon hyposmia being defined as participants scoring 
0/7, ≤ 1/7, ≤ 2/7, ≤ 3/7, ≤ 4/7, ≤ 5/7, and ≤ 6/7. The different 
thresholds for each combination of 7 smell subsets meant 
that we assessed 130,504,920 sets of smell combinations 
and hyposmia thresholds. Combining this with the same 
approach for 1–6 smell subsets led to the assessment of a 
total 157,222,040 possible screening tests.
A “winning” subset of smells at each hyposmia threshold 
was selected according to those with the highest combined 
sensitivity and specificity. For example, when consider-
ing 5 smell items at a threshold of ≤ 4 to define hyposmia, 
sensitivity was the number of people who both correctly 
identified ≤ 4 of the 5 smells and were defined as hypos-
mic according to the full UPSIT, divided by the total num-
ber of hyposmic participants according to the full UPSIT. 
Fig 1  Schematic workflow of 
PREDICT-PD participation in 
year 0 and year 3 and where 
UPSIT data were available for 
‘discovery’ and ‘validation’ 
analysis
 Journal of Neurology
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Specificity was the number of people who correctly identi-
fied all 5 smells in the subset and were not hyposmic accord-
ing to the full UPSIT, divided by all those who were not 
hyposmic as defined by the full UPSIT. These two values 
were then summed and the combination of smells with the 
highest combined value was deemed to be the “winner” 
for that specific threshold. The same process was repeated 
for every threshold of hyposmia, for all numbers of smell 
combinations.
Using this method, rather than the area under curve 
(AUC), allowed us to identify the best performing combi-
nations of smells across all possible thresholds, rather than 
one which performed best when averaging across a number 
of thresholds (as an AUC would). Hence, it allowed us to 
identify threshold-specific optimal smell subsets and enable 
comparison of different hyposmia thresholds.
The screening performance of each “winning” subset was 
reassessed in an independent group of 191 healthy PRE-
DICT-PD participants (validation cohort). There was no 
overlap in the participants included for selecting the “win-
ning” subsets and the subsequent testing of them (Fig. 1). 
Therefore, the results reported are more likely to be gener-
alisable and not due to overfitting of the model.
Validation of the novel smell subsets in individuals 
with PD
We then evaluated smell identification in the context of PD. 
We compared the proportion of smells correctly identified 
by 40 individuals with PD and the healthy PREDICT-PD 
participants for all 40 UPSIT items. For the top 10 smells 
with the largest difference in correct identification between 
individuals with PD and healthy controls, we looked at how 
commonly these featured in our “winning” smell subsets 
from the previous phase of the analysis. “Winning” smell 
subsets containing at least 2 of the top 10 discriminatory 
smells were subsequently assessed for their screening per-
formance in detecting hyposmia in the same individuals with 
PD, compared to currently available PST and BSIT tests.
Results
Based on total UPSIT scores and age- and sex-specific 
thresholds of PREDICT-PD participants, 16.2% females 
(89/548) and 16.0% males (55/343) from the 891 partici-
pants in the discovery cohort were classified as having 
hyposmia. Smoke was the most common correctly identified 
smell (851/891), and turpentine the least common correctly 
identified smell (328/891). Of the 191 validation cohort par-
ticipants, 13.6% females (16/118) and 24.7% males (18/73) 
were hyposmic. Amongst the 40 PD participants who were 
sent and completed the UPSIT, 70% females (7/10) and 
83.3% males (25/30) were hyposmic, in keeping with the 
known higher prevalence of hyposmia in PD patients com-
pared to healthy participants [3].
PST and BSIT hyposmia screening performance
Table 1 displays the screening performances of abbreviated 
smell tests assessed in the discovery cohort. Using the rec-
ommended cut-off score of ≤ 3 correctly identified smells to 
denote hyposmia, PST Version A detected hyposmia with 
sensitivity 76.8%, specificity 64.9%, PPV 29.3%, and NPV 
93.6%. PST Version B had a greater sensitivity 88.6% and 
NPV 94.8%, but lower specificity 45.9% and PPV 23.3%. 
For the 12-item BSITs, the standard cut-off score of ≤ 9 on 
BSIT-A detected hyposmia with a sensitivity of 83.1%, spec-
ificity 79.5%, PPV 43.5%, and NPV 96.1%. Comparatively, 
BSIT-B had greater sensitivity 96.5% and NPV 98.7% than 
BSIT-A, but less specificity 51.8% and PPV 27.5%. We also 
assessed different score thresholds of the BSIT, which are 
presented in full in Supplementary Tables 2 and 3. 
Identifying optimal smell subsets
We next assessed all combinations of 1–7 smells from the 
full set of 40 UPSIT smells in the discovery cohort, from 
which there was a total of 28 “winning” smell combinations. 
Table 2 shows a selection of these “winning” smell combi-
nations and the threshold scores for defining hyposmia. The 
sensitivity, specificity, PPV, and NPV values shown are from 
their assessment in both discovery and validation cohorts. 
The complete results from the data-driven analysis with all 
Table 1  Screening performance 
of PST and BSIT Versions A 
and B for hyposmia detection 
in discovery cohort compared 
against the UPSIT
PPV positive predictive value, NPV negative predictive value
Shorter test version Number of 
smells
Hypos-
mia score
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
PST Version A 4  ≤ 3 76.8 64.9 29.3 93.6
PST Version B 4  ≤ 3 86.6 45.9 23.3 94.8
BSIT-A 12  ≤ 9 83.1 79.5 43.5 96.1
BSIT-B 12  ≤ 9 96.5 51.8 27.5 98.7
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28 “winning” smell combinations at each threshold are pre-
sented in full in Supplementary Tables 4 and 5, showing 
their screening performance in the discovery and validation 
cohorts, respectively.
Table 2 reveals that the “winning” smell subsets have dif-
ferent relative strengths in terms of sensitivity, specificity, 
PPV, and NPV. In both discovery and validation cohorts, 
optimised combinations of 7 smell items showed superior 
screening performance to the 12-item BSITs. 7 smells using 
a cutoff of 4 for hyposmia surpassed the sensitivity/specific-
ity of BSIT-A (88.2/85.4 vs 83.1/79.5) and another 7 smells 
with a hyposmia cutoff of 5 surpassed that of the more sen-
sitive BSIT-B (100/53.5 vs 96.5/51.8). Using as few as 6 
smell items produced comparable screening performance to 
the 12-item BSIT (sensitivity/specificity for 6 smells with a 
cutoff of 3: 85.3/78.3 vs 83.1/79.5 for BSIT-A). Following 
acquisition of these results, further analysis of smell com-
binations using > 7 UPSIT items was deemed unnecessary 
and was not pursued.
For the purpose of designing a short pre-screening smell 
test, which would best identify individuals who require fur-
ther smell testing, it was important to maximise sensitivity 
and NPV to minimise the number of impaired individu-
als excluded from further testing. In this regard, a 4-item 
subset (menthol, clove, gingerbread, orange) with a cutoff 
of 3 or less produced higher sensitivity and NPV scores in 
both discovery and validation cohorts when compared with 
both current 4-item PST tests (see Table 1, Supplementary 
Table 4 and Table 2).
Comparison of smell identification between PD 
and healthy participants
The results from a comparison of correctly identified UPSIT 
smell items in the 40 patients with PD and the 891 healthy 
PREDICT-PD participants are shown in Fig. 2.
The most discriminating smells (i.e., those with the larg-
est differences in correct identification between PD patients 
and PREDICT-PD controls) included menthol, orange, and 
coconut, while the least discriminating smells included tur-
pentine, grape, and grass. Interestingly, several of the most 
discriminating smells frequently featured within the “win-
ning” UPSIT combinations chosen for hyposmia detection 
in healthy individuals from the data-driven analysis (Sup-
plementary Tables 4 and 5).
Based on these findings, we assessed the screening per-
formance of “winning” smell subsets containing at least 2 
of the top 10 discriminatory smells in accurately detect-
ing hyposmia (by UPSIT) in the 40 PD patients within this 
study, compared to the performance of current PST and 
BSIT versions (see Table 3). Improved screening perfor-
mance was observed in “winning” smell subsets that con-
tained discriminating smells, with subsets containing ≥ 4 
discriminating smells all having 100% sensitivity for detect-
ing hyposmic PD patients. This included the more ‘PD-
specific’ BSIT-B, which contained 5/10 top discriminatory 
smells. Significantly, the 4-item combination of menthol, 
clove, gingerbread and orange used in 4 and 5-item subsets 
had the highest performance score for both sensitivity and 
specificity (100% and 87.5%) than all other smell combina-
tions, surpassing the performance of both 12-item BSITs. In 
addition, the use of the 2-item subset of clove and coconut 
had a higher/equal sensitivity to 4-item PST-B and PST-
A, respectively. However, in some smell subsets, higher 
numbers of discriminating smells appeared to decrease 
Fig. 2  Identification rates of the 40 individual smells in the full 
UPSIT in 40 PD participants (blue) and 891 healthy PREDICT-PD 
controls (red).  Smells are ordered by those with the greatest differ-
ence in correct smell identification by PD participants’ versus healthy 
controls on the left
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specificity; for example, the specificity was reduced from 
25% to 12.5% in the 4-item combination of cherry, clove, 
coconut and root beer, compared to the 2-item combination 
of clove and coconut.
Discussion
In the first part of this study, we assessed the screening 
performance of abbreviated UPSIT smell subsets for their 
ability to detect hyposmia within a large UK-based popula-
tion of healthy individuals in the PREDICT-PD study. On 
assessment of the current commercially available BSIT and 
PST smell tests (Versions A and B), the 12-item BSITs had 
an expected greater screening performance for detecting 
hyposmia compared with either 4-item PST. This reflects 
the BSITs’ ability to act as standalone tests for hyposmia, 
whereas PSTs are intended as a pre-screen to target subse-
quent administration of full UPSIT testing. However, our 
results highlighted differences in the sensitivity and speci-
ficity of each 4-item PST, suggesting that the accuracy with 
which they can detect hyposmia varies depending on the 
version administered, which should be taken into considera-
tion with future use.
In our data-driven analysis, we identified novel UPSIT 
subsets of just 7 smell items that had superior screening 
performance compared to the 12-item BSITs for detecting 
hyposmia in healthy PREDICT-PD individuals. Importantly, 
these “winning” smell subsets identified in the discovery 
phase appeared to retain their overall screening performance 
with independent testing in the validation phase. Using as 
few as 6 smell items could offer comparable screening per-
formance to the BSIT. Given that these combinations are 
half the length of the current BSIT, expansion of their use 
could offer obvious benefits in terms of time and expense 
when undertaking large-scale studies, or for use in routine 
clinical settings.
We also identified a subset of 4 smells (menthol, clove, 
gingerbread, and orange) which had a high-screening perfor-
mance in the discovery cohort, and identified a greater pro-
portion of individuals with hyposmia than either Version A 
or B of the 4-item PST when reassessed in the independent 
validation group. While the above 7 and 6 item tests may be 
suitable for standalone testing, this optimised 4-item subset 
may be an ideal pre-screen test, before selective use of the 
UPSIT for assessing olfactory dysfunction in the general 
population. Nevertheless, it is still important to remember 
that while shorter test versions may provide an effective 
method for hyposmia screening, they do not have the added 
benefits that longer tests offer in being able to distinguish 
between levels of less-than-total olfactory dysfunction or 
for identifying malingering, hence should not be seen as a 
substitute for more extensive forms of smell testing.
In the context of assessing hyposmia in PD, studies have 
consistently demonstrated that PD patients have lower total 
UPSIT scores compared with healthy controls [25, 26], 
which was borne out in our results. In the second part of 
this study, we attempted to investigate whether any of our 
Table 3  Screening performance for detecting hyposmia defined by the UPSIT in PD patients using “winning” smell subsets which contain at 
least 2 of the 10 most discriminating smell and current abbreviated smell tests
Smell subsets are ordered according to their respective sensitivities, then by specificity. The most discriminating smells are highlighted in bold
Total no. 
of smells
No. of dis-
criminatory 
smells
Hyposmia 
cut-off score
Abbreviated smell test Sensitivity (%) Specificity (%)
4 4  ≤ 3 Menthol, Clove, Gingerbread, Orange 100 87.5
5 4  ≤ 4 Menthol, Clove, Gingerbread, Orange, Onion 100 87.5
12 5  ≤ 9 BSIT-B (includes, Clove, Coconut, Lemon, Wintergreen, 
Banana)
100 62.5
7 5  ≤ 5 Menthol, Cherry, Clove, Gingerbread, Orange, Pine, Pizza 100 37.5
6 5  ≤ 4 Menthol, Cherry, Clove, Gingerbread,orange, Root beer 100 12.5
7 2  ≤ 6 Menthol, Clove, Leather, Lilac, Watermelon, Smoke, Rose 96.9 37.5
6 3  ≤ 5 Menthol, Clove, Gingerbread, Lilac, Watermelon, Smoke 96.9 25
3 3  ≤ 2 Menthol, Clove, Coconut 96.9 25
5 4  ≤ 3 Menthol, Cherry, Clove, Coconut, Root beer 96.9 12.5
7 3  ≤ 4 Cherry, Clove, Gingerbread, Fruit punch, Root beer, Pine, Mint 96.9 12.5
12 2  ≤ 9 BSIT-A (includes Lemon, Banana) 90.6 25
4 0  ≤ 3 PST-A (none) 81.3 37.5
2 2  ≤ 1 Clove, Coconut 81.3 25
4 3  ≤ 2 Cherry, Clove, Coconut, Root beer 81.3 12.5
4 0  ≤ 3 PST-B (none) 75 25
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“winning” shorter smell subsets also had value in assessing 
hyposmia in patients with PD. Specifically, we assessed dif-
ferences in correct smell identification responses between 
the 40 PD and 891 healthy PREDICT-PD individuals of this 
study to investigate for discriminatory smells. Interestingly, 
menthol, clove, gingerbread, and orange featured amongst 
the top 10 discriminatory smells, and when included within 
4- and 5-item subsets correctly identified hyposmia in all 
of the 32 hyposmic patients with PD, as well as correctly 
classified 7 of the 8 normosmic patients with PD (sensitiv-
ity/specificity 100% and 87.5%), surpassing the screening 
performance of both 12-item BSITs. Further investigation 
into the utility of these smell subsets for hyposmia detection 
in larger PD cohorts would be of benefit. However, while 
the present study demonstrates the ability of certain smell 
subsets to detect hyposmia in individuals with PD (as well 
as the healthy population), it does not offer confirmatory 
evidence of there being a PD-specific patterns of olfactory 
dysfunction. Formal comparison with hyposmia due to other 
causes would be required to make claims as to such disease-
specific detection.
Indeed, there has been extensive debate as to whether 
specific smells are lost preferentially over the course of 
PD. Some work suggests that specific smells can differenti-
ate people with and without PD [27–29]; however, there 
is significant variability between which smells are impli-
cated, while others have found no evidence of PD-specific 
smell loss [25, 20]. By example, a recent study attempting to 
devise novel UPSIT subsets specific for the detection of PD 
found subsets with good screening performance in discovery 
analyses, but failed to retain this performance when reas-
sessed in independent groups [19]. Overall, these variable 
findings may be due to several confounding factors, includ-
ing the choice of smell test, alternative smell (‘distractor’) 
options, study populations, and cultural differences.
Alternative methods to increase the screening perfor-
mance of smell tests for identifying individuals at risk of 
PD have also been investigated. These methods include 
combination of smell scores with other early, nonmotor PD 
manifestations, such as constipation, sleep disturbances, and 
depression [16, 31]. Moreover, another recent study identi-
fied a PD-specific response pattern of 12 incorrect UPSIT 
question/response pairs in PD participants compared to 
healthy controls [32], which appeared more valuable for PD 
diagnosis than total mean UPSIT score. Assessing for this 
sort of disease-specific olfactory loss was beyond the scope 
of the present study, but would certainly merit further work 
in the future. Additional adaptations in the design of future 
smell tests could also include the use of confidence ratings 
into each answer panel, ranking from 1 (least confident) to 
4 (very confident), to provide a greater yield of information 
over individuals’ identification of specific smells without 
lengthening the test.
A key strength of the present study is its size. To the best 
of our knowledge, this is the largest assessment of screening 
performance of abbreviated versions of smell identification 
tests in comparison with the full 40-item UPSIT. However, 
there are certain limitations. First, given that the assessment 
of all of abbreviated smell tests was based upon comparison 
with participants’ total UPSIT score, we are assuming that 
it still remains an accurate and sensitive tool for detecting 
hyposmia in the general healthy population as validated by 
Doty et al. [33]. The three ‘distractor’ options used in both 
PST versions may also differ from those for the same smells 
in the full UPSIT test (see Supplementary Table 6). These 
different distractors could have influenced participants’ abil-
ity to identify the smells to some degree, but the impact 
on overall screening performance assessed is likely to be 
relatively small, given that the target smells are the same. In 
the same way, given that our data-driven analysis of multiple 
UPSIT smell combinations was based on existing UPSIT 
data from participants, we acknowledge the potential influ-
ence of distractor options for each smell on the correct iden-
tification, and thus the ranking of “winning” smell subsets.
Another limitation is that the current study used the origi-
nal US version of the UPSIT, but in a UK population, which 
might have lowered overall performance due to reduced 
familiarity with some of the smells. For example, the win-
tergreen smell is likely to be more familiar to an American 
population than in the UK. Indeed, a previous UK-based 
study using the US UPSIT found certain smells to have low 
identification rates [34]. The smells with the lowest cross-
cultural detection included root beer (52.3%), lime (56.8%), 
dill pickle (61.4%), and turpentine (65.9%) [34], which was 
borne out in our own data as some of the poorest identified 
smells in healthy participants, as well as the worst discrimi-
nating smells between PD patients and healthy participants. 
Of note, turpentine and grape were the only two smells 
within our study that had a higher correct detection by PD 
patients than healthy participants. In light of these issues, 
“winning” subsets which only include smells present in the 
UK UPSIT version are provided in Supplementary Table 7.
Finally, while the current study identified individuals 
as ‘hyposmic’ based on specific age and sex threshold cut-
offs within the PREDICT-PD population, the data-driven 
approach did not include age or sex in their parameters 
for assessment of “winning” USPIT smell subsets at each 
threshold cutoff. Given the established influence of age and 
sex on olfaction [2, 35], it is possible that their inclusion 
in the analysis could lead to further improvement in the 
screening performance of abbreviated subsets, and this will 
be evaluated in future work.
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Conclusion
Accurate assessment of olfactory dysfunction may assist 
in the early detection of certain neurodegenerative dis-
eases such as PD. Using a data-driven approach, our study 
identified several “winning” 1–7 UPSIT smell subsets with 
high-screening performance for hyposmia detection in 891 
healthy participants of the PREDICT-PD study. Of note, 
7-item subsets demonstrated superior screening performance 
to current 12-item BSIT versions, which was retained on 
reassessment within an independent cohort. Our study also 
found that “winning” subsets containing smells which had 
large differences in correct identification rates between indi-
viduals with and without PD also produced high-screening 
performances when assessing for hyposmia in individu-
als with PD, including menthol, clove, gingerbread, and 
orange. Notably, several 3-, 4-, and 5-item subsets incorpo-
rating some of the top 10 discriminatory identified more PD 
patients with hyposmia than current PST and even BSIT-A 
test versions. Significant cost and efficiency savings may be 
gained using these smell combinations within an abbrevi-
ated smell test to target more focused administration of the 
full UPSIT for wider scale clinical and research purposes, 
in both general and PD-related settings.
Acknowledgements The authors would like to thank and acknowledge 
all of the participants who have helped support and contribute to the 
PREDICT-PD project. The authors would also like to remember and 
acknowledge the valuable contributions from the late Selina Paul to the 
project, who worked tirelessly to support its aims.
Author contributions TJ, SA, and AJN were involved in the design and 
conceptualisation of this study, the analysis and interpretation of data, 
and drafting of the manuscript for intellectual content, and later revi-
sions. LS and DR were responsible for acquisition and cleaning of data, 
and revising the manuscript for intellectual content. JC, GG, AL, and 
AS were involved in the design and conceptualisation of the PREDICT-
PD study and revised the current manuscript for intellectual content.
Funding No specific funding for this work. The Preventive Neurology 
Unit is funded by the Barts Charity and the PREDICT-PD study is 
funded by Parkinson’s UK.
Compliance with ethical standards 
Conflicts of interest Alastair Noyce holds research grants from Parkin-
son’s UK, the Leonard Wolfson Experimental Neurology Centre, the 
UCL Movement Disorders Centre, and the Virginia Kieley Benefac-
tion. He has received personal fees from Britannia Pharmaceuticals 
and Profile Pharmaceuticals. Andrew Lees is funded by the Reta Lila 
Weston Institute of Neurological Studies, University College Lon-
don, Institute of Neurology and reports consultancies from: Britannia 
Pharmaceuticals and BIAL Portela. He also reports grants and/or re-
search support from the Frances and Renee Hock Fund, and honoraria 
from Britannia, Profile Pharma, UCB, Roche, BIAL, STADA Nordic, 
Nordiclnfu Care, and NeuroDerm. Anette  Schrag was supported by 
the National Institute for Health Research University College Lon-
don Hospitals Biomedical Research Centre, and reports grants from 
Economic and Social Research Council, GE Healthcare, Parkinson’s 
UK, European Commission, Movement Disorders Society, National 
Institute of Health and the Royal Free Hospital charity, and received 
personal fees from Medtronic. The remaining authors declare that they 
have no conflict of interest.
Ethical standards The study was conducted with the approval of the 
local research ethics committee and has been performed in accordance 
with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments. All persons gave their informed consent 
prior to their inclusion in the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Murphy C, Schubert CR, Cruickshanks KJ, Klein BEK, Klein R, 
Nondahl DM (2002) Prevalence of olfactory impairment in older 
adults. J Am Med Assoc 288(18):2307–2312
 2. Doty RL (1989) Influence of age and age-related diseases on 
olfactory function. Ann N Y Acad Sci 561:76–86
 3. Doty RL (2012) Olfaction in Parkinson’s disease and related dis-
orders. Neurobiol Dis 46(3):527–552
 4. Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleis-
chmann J, Silburn PA et al (2009) Prevalence of smell loss in 
Parkinson’s disease—a multicenter study. Park Relat Disord 
15(7):490–494
 5. Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K et al 
(2016) Diagnosis of Parkinson’s disease on the basis of clinical 
and genetic classification: a population-based modelling study. 
Lancet Neurol 14(10):1002–1009
 6. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki 
K et al (2008) Association of olfactory dysfunction with risk for 
future Parkinson’s disease. Ann Neurol 63(2):167–173
 7. Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk 
populations for Parkinson’s disease: lessons from ongoing studies. 
Mov Disord 27(5):656–665
 8. Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, 
Ascherio A et al (2012) Impaired olfaction and other prodromal 
features in the Parkinson at-risk syndrome study. Mov Disord 
27(3):406–412
 9. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, 
Reichmann H (2007) Olfactory loss may be a first sign of idi-
opathic Parkinson’s disease. Mov Disord 22(6):839–842
 10. Titova N, Chaudhuri KR (2017) Nonmotor Parkinson’s and future 
directions. Int Rev Neurobiol 134:1493–1505
 11. Del Tredici K, Rüb U, De Vos RAI, Bohl JRE, Braak H (2002) 
Where does Parkinson disease pathology begin in the brain? J 
Neuropathol Exp Neurol 61(5):413–426
 12. Beach TG, Adler CH, Lue LF, Sue LI, Bachalakuri J, Henry-Wat-
son J et al (2009) Unified staging system for Lewy body disorders: 
correlation with nigrostriatal degeneration, cognitive impairment 
and motor dysfunction. Acta Neuropathol 117(6):613–634
 13. Attems J, Walker L, Jellinger KA (2014) Olfactory bulb 
involvement in neurodegenerative diseases. Acta Neuropathol 
127(4):459–475
 Journal of Neurology
1 3
 14. Haehner A, Hummel T, Reichmann H (2009) Olfactory dysfunc-
tion as a diagnostic marker for Parkinson’s disease. Expert Rev 
Neurotherapeutics 9(12):1773–1779
 15. Morley JF, Duda JE (2010) Olfaction as a biomarker in Parkin-
son’s disease. Biomark Med 4(5):661–670
 16. Fullard ME, Morley JF, Duda JE (2017) Olfactory dysfunction 
as an early biomarker in Parkinson’s disease. Neurosci Bull 
33(5):515–525
 17. Hawkes CH, Doty RL (eds) (2018) Measurement of olfaction. 
In: smell and taste disorders. Cambridge University Press, Cam-
bridge, pp 80–137
 18. Doty RL, Shaman P, Dann M (1984) Development of the Uni-
versity of Pennsylvania Smell Identification Test: a standard-
ized microencapsulated test of olfactory function. Physiol Behav 
32(3):489–502
 19. Morley JF, Cohen A, Silveira-Moriyama L, Lees AJ, Williams 
DR, Katzenschlager R et al (2018) Optimizing olfactory testing 
for the diagnosis of Parkinson’s disease: item analysis of the Uni-
versity of Pennsylvania Smell Identification Test. npj Park Dis 
4(1):2
 20. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH 
et al (2005) A 10-item smell identification scale related to risk 
for Alzheimer’s disease. Ann Neurol 58(1):155–160
 21. Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dys-
function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 
62(5):436–446
 22. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, 
Knowles CH, Hardy J et al (2014) PREDICT-PD: identifying risk 
of Parkinson’s disease in the community: methods and baseline 
results. J Neurol Neurosurg Psychiatry 85(1):31–37
 23. Rawal S, Hoffman HJ, Honda M, Huedo-Medina TB, Duffy VB 
(2015) The taste and smell protocol in the 2011–2014 US National 
Health and Nutrition Examination Survey (NHANES): test-retest 
reliability and validity testing. Chemosens Percept 8(3):138–148
 24. Doty RL, Marcus A, Lee WW (1996) Development of the 12-item 
Cross-Cultural Smell Identification Test (CC-SIT). Laryngoscope 
106(3 Pt 1):353–356
 25. Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in 
parkinsonism: a general deficit unrelated to neurologic signs, dis-
ease stage, or disease duration. Neurology 38(8):1237–1244
 26. Doty R (2012) Olfactory dysfunction in Parkinson disease. Nat 
Rev Neurol 8(6):329–339
 27. Double KL, Rowe DB, Hayes M, Chan DKY, Blackie J, Corbett A 
et al (2003) Identifying the pattern of olfactory deficits in Parkin-
son disease using the brief smell identification test. Arch Neurol 
60(4):545–549
 28. Daniel SE, Hawkes CH (1992) Preliminary diagnosis of Parkin-
son’s disease by olfactory bulb pathology. Lancet 340(8812):186
 29. Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis 
CA, Studenski SA et al (2007) Selective hyposmia and nigros-
triatal dopaminergic denervation in Parkinson’s disease. J Neurol 
254(1):84–90
 30. Hummel T, Storch A, Baptista RB, Maboshe W, Hähner A, Reich-
mann H (2013) Selective hyposmia in Parkinson’s disease? J Neu-
rol 447(1):12–16
 31. Noyce AJ, R’Bibo L, Peress L, Bestwick JP, Adams-Carr KL, 
Mencacci NE et al (2017) PREDICT-PD: an online approach to 
prospectively identify risk indicators of Parkinson’s disease. Mov 
Disord 32(2):219–226
 32. Gerkin RC, Adler CH, Hentz JG, Shill HA, Driver-Dunckley E, 
Mehta SH et al (2017) Improved diagnosis of Parkinson’s dis-
ease from a detailed olfactory phenotype. Ann Clin Transl Neurol 
4(10):714–721
 33. Doty RL, Shaman P, Kimmelman CP, Dann MS (1984) Univer-
sity of Pennsylvania Smell Identification Test: a rapid quantita-
tive olfactory function test for the clinic. Laryngoscope 94(2 Pt 
1):176–178
 34. Muirhead N, Benjamin E, Saleh H (2013) Is the University of 
Pennsylvania Smell Identification Test (UPSIT) valid for the UK 
population? Otorhinolaryngologist 6(2):99–10
 35. Choudhury ES, Moberg P, Doty RL (2003) Influences of age 
and sex on a microencapsulated odor memory test. Chem Senses 
28(9):799–805
